Serotonin-Dopamine Activity Modulators Market
Number of pages: 100 | Report Format: PDF | Published date: April 10, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
3.2% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug, Application, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global serotonin-dopamine activity modulators market is expected to register a revenue CAGR of 3.2% during the forecast period 2023 to 2031.
Serotonin-Dopamine Activity Modulators Market Fundaments
Serotonin-Dopamine Activity Modulators (SDAMs) are medicines used to treat psychiatric illnesses such as schizophrenia and bipolar disorder. SDAMs alleviate psychiatric symptoms by regulating the action of serotonin and dopamine, two neurotransmitters involved in mood and feeling control. Furthermore, neurotransmitters are substances nerve cells (neurons) produce to convey nerve impulses. Each neurotransmitter attaches to a different sort of receptor on the neuronal membrane. Receptors are protein molecules that start downstream action within the cell in reaction to neurotransmitter stimulation. Dopamine, also known as the "happy hormone," controls the brain's reward system and is responsible for the feeling of happiness and other functions such as movement, emotions, and reasoning. Serotonin controls most bodily processes, including sleep, digestion, cognition, emotion, and behavior. SDAMs influence serotonin and dopamine neurotransmission by increasing inhibitory receptor activity and inhibiting excitatory receptors. Some SDAMs also affect neurotransmitters, such as norepinephrine, which is implicated in mood, focus, and vitality.
Each SDAM operates in a distinct manner, which includes the following: Some SDAMs act as a partial agonist at activating D2 dopamine receptors and inhibiting 5-HT1A serotonin receptors. Partial agonists either increase or inhibit receptor function depending on neurotransmitter concentration levels. It also acts as a blocker at activating 5-HT2A serotonin receptors. Antagonists inhibit receptor activity, whereas agonists stimulate receptor activity. It acts as a D2 and 5-HT2A receptor blocker, which are thought to be implicated in insanity. However, other SNDRIs have been developed as possible antidepressants and therapies for various conditions, including obesity, cocaine addiction, attention deficit hyperactivity disorder (ADHD), and chronic pain. They are a development of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), including dopaminergic action believed to increase the therapeutic effect.
However, compared to their SSRI and SNRI peers, these drugs may cause more adverse effects and abuse. SNDRIs, non-selective monoamine oxidase inhibitors (MAOIs) like phenelzine and tranylcypromine, enhance the action of all three main monoamine neurotransmitters. For the same reason, they are comparable to serotonin-norepinephrine-dopamine releasing agents (SNDRAs) such as MDMA ("ecstasy") and dimethyltryptamine (ET).
Serotonin-Dopamine Activity Modulators Market Dynamics
The rising incidence of bipolar disorder, rising initiatives by government agencies to raise consciousness, and technical developments are the main factors driving market expansion. According to an essay released in October 2021 titled "What is the worldwide prevalence of bipolar disorder," bipolar disorder has a lifelong prevalence of about 1% and a one-year prevalence of about 0.5% worldwide. Bipolar I illness is more common than bipolar II conditions. According to World Health Organization (WHO), important statistics revised in June 2022, one in every eight individuals worldwide suffers from a mental illness. Because of the COVID-19 pandemic, the number of individuals suffering from worry and depression skyrocketed in 2020. Initial estimates show a 26% and 28% rise in depressive and anxiety disorders in just one year. According to the same authority, 40 million individuals were expected to suffer from bipolar disorder by 2020. Bipolar disorder patients have alternating melancholy and euphoric symptoms. According to a March 2022 paper titled "The prevalence and clinical correlates of medical disorders comorbidities in patients with bipolar disorder," medical issues are prevalent in Chinese bipolar disorder (BD) victims. Concomitant medical illnesses in BD patients are related to smoking, the number of depressive episodes, the start age, and the illness's length.
Moreover, there is a higher understanding of mental illness, particularly major mental disorders like schizophrenia. The catastrophic crippling effects of undiagnosed schizophrenia on the patient have significantly impacted the global serotonin-dopamine activity modulators market development. Several trends, including increased awareness of mental disorders, increased medical interventions for the treatment of major mental disorders, a robust pipeline, increasing adoption of advanced schizophrenia therapeutics in emerging markets, and an increase in the number of schizophrenia patients, have all contributed to the growth of the serotonin-dopamine activity modulators market. Furthermore, several established and developing nations' healthcare institutions are focusing more on mental health, contributing to market growth.
Serotonin-Dopamine Activity Modulators Market Ecosystem
The global serotonin-dopamine activity modulators are analyzed from four perspectives: drug, application, end user, and region.
Serotonin-Dopamine Activity Modulators Market by Drug
[98763]
Based on the drug, the global serotonin-dopamine activity modulators have been segmented into lumateperone, olanzapine, brexpiprazole, and others.
The lumateperone segment showed lucrative revenue growth during the forecast period. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for treating schizophrenia. It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin, and dopamine, all neurotransmitters contributing to the pathophysiology of schizophrenia. Lumateperone (ITI-007) is an atypical antipsychotic useful in treating schizophrenia and ultimately driving the segment. Lumateperone has a distinct receptor binding profile, enabling it to address schizophrenia-related symptoms while minimizing side effects. Unlike second-generation antipsychotics like lurasidone and brexpiprazole, lumateperone acts as a partial agonist and a blocker at pre and postsynaptic dopamine (D2) receptors. Patients with mild or serious hepatic dysfunction (Child-Pugh class B or C) have greater lumateperone plasma concentrations than those with typical hepatic function. As a result, individuals with mild or severe hepatic impairment should take half the suggested daily dose.
However, many companies add to market development by launching new products. For instance, Zydus Cadila received US Food and Drug Administration (USFDA) clearance in December 2021 to sell the generic medication Cariprazine capsules used in treating schizophrenia. In addition, Intra-Cellular Therapies, Inc. announced in December 2021 that the US Food and Drug Administration (FDA) approved CAPLYTA for treating depressive episodes associated with bipolar I or II disorder in adults, both as monotherapy and in combination with lithium or valproate.
Serotonin-Dopamine Activity Modulators Market by Application
The global serotonin-dopamine activity modulators are segmented based on application into schizophrenia, bipolar disorder, and others.
The bipolar disorder segment is expected to show significant revenue growth during the forecast period. Bipolar disease is also used "off label" as sedatives for sleeplessness, anxiety, and/or restlessness mood-stabilizing medication can reduce the signs of mania until mood stabilizers take full effect in people taking antipsychotics. Some antipsychotics can stabilize moods independently and may be used as long-term therapy for individuals who do not tolerate or react to lithium or anticonvulsants. Asenapine (Saphris), aripiprazole (Abilify), cariprazine (Vraylar), and clozapine (Clozaril), lurasidone (Latuda), quetiapine (Seroquel), olanzapine (Zyprexa), risperidone (Risperdal), and ziprasidone are some antipsychotic medications. (Geodon).
Serotonin-Dopamine Activity Modulators Market by Distribution Channel
The global serotonin-dopamine activity modulators are segmented based on the distribution channel into hospital pharmacy, retail pharmacy, and online pharmacy.
The hospital pharmacy segment is growing, owing to major clinicians who continue to practice in major hospitals and the rise of long-acting injectables, which physicians may use in their normal practice. Regarding other delivery modes, retail pharmacists and online pharmacies are expected to be the next most prominent segments, owing to the fulfillment of orders following the original diagnosis. Online pharmacies are expected to grow fastest due to increased worldwide access to Internet facilities and the resultant comfort and ease of purchasing or completing medications from the luxury of residences and other locations.
Serotonin-Dopamine Activity Modulators Market by Region
The global serotonin-dopamine activity modulators are segmented based on region into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America is expected to dominate the market with the largest revenue share during the forecast period. The rapid adoption of advanced schizophrenia drugs across the region is expected to fuel the regional market's revenue growth. Furthermore, rising consciousness, increased demand for effective drugs, and an increasing number of schizophrenic patients are anticipated to drive the development of North America's serotonin-dopamine activity modulators market during the projection period. Additionally, knowledge and consciousness about the remedial steps for any mental disorder were minimal, resulting in less demand for excellent bipolar disorder medicine made by pharmaceutical companies. However, with the rise of digital media in recent years, approval of methods for bipolar therapy is mirrored in an enormous increase in sales of over-the-counter meds for bipolar cases. There is also some old-age natural medication for bipolar disorder that pharmaceutical firms are constantly researching and developing to expand their client base. Many market participants have established brand values by providing mood stabilizers to customers online.
Asia Pacific is expected to have the highest market revenue growth in the area. Increasing consciousness and emphasis on mental health is a major driver for the region's industry. Healthcare workers and businesses from India, China, Japan, and the rest of Asia Pacific are interested in the effective delivery of schizophreniamedicines and the region's new product releases.
Competitive Landscape of the Global Serotonin-Dopamine Activity Modulators Market
H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. are occupied with creating schizophrenia treatment drugs to expand and strengthen their market position. A larger emphasis is being placed on creating long-acting injectables and newer generations of schizophrenia medications. Alkermes has constantly been researching schizophrenia drugs like ALKS 3831. ALKS 3831 is a drug that combines olanzapine and samidorphan. ALKS 3831 was able to effectively reduce the weight increase experienced by schizophrenia patients and report a good Phase 3 clinical trial outcome.
The prominent market players operating in the global serotonin-dopamine activity modulators market include:
Strategic Development in Serotonin-Dopamine Activity Modulators Market
Serotonin-Dopamine Activity Modulators (SDAMs) are medicines for treating psychiatric illnesses such as schizophrenia and bipolar disorder. SDAMs alleviate psychiatric symptoms by regulating the action of serotonin and dopamine, two neurotransmitters involved in mood and feeling control. Neurotransmitters are substances nerve cells (neurons) produce to convey nerve impulses.
Asia Pacific is the key growth region in the global serotonin-dopamine activity modulators market.
The increasing prevalence of bipolar disorders and rising initiatives by government institutes to increase awareness drive market revenue growth.
Some prominent market players in the global serotonin-dopamine activity modulators market include Janssen Pharmaceuticals, Bristol-Myers Squibb Company, AstraZeneca, and others.
The lumateperone segment shows the highest revenue growth during the forecast period.
*Insights on financial performance are subject to the availability of information in the public domain
Frequently Asked Questions About This Report
What is the definition of the serotonin-dopamine activity modulators market?
Which is the key growth region in the global serotonin-dopamine activity modulators market?